Recombinant Versus High-sensitivity Conventional Thromboplastin: A Randomized Clinical Study in Patients on Oral Anticoagulation

Summary

A prospective, randomized, double-blind clinical trial was carried out in a single center to compare the clinical and laboratory quality of oral anticoagulant therapy monitored with recombinant tissue factor (RTF) or with a sensitive, human-derived, conventional thromboplastin (CT) in the PT test. Seven hundred and fifty-seven consecutive patients receiving oral anticoagulation for various indications were randomized to RTF (n = 379) or CT (n = 368) for 6 months. Total follow-up was 167 and 153 patient-years for RTF and TP groups respectively. Fifty-six bleeding events were observed: 31 in the RTF group and 25 in the TP group. The incidence of bleeding was 18.5 and 16.5% pt-yrs for RTF and TP patients respectively (n.s.). The event-free follow-up curves were not significantly different between the two groups. The laboratory quality of oral anticoagulation was evaluated with the “last check in file” method: therapeutic INR was found in the same propor-tipn of RTF and TP patients (70.2% vs 68.8%). Our study shows that RTF is as effective as a sensitive, conventional thromboplastin for monitoring oral anticoagulation.

• References

• 1 Spicer EK, Horion R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin TC, Nemerson Y, Konisberg WH. Isolation of cDNA coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA 1987; 84: 5148-5152
• 2 Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50: 129-135
• 3 Rehemtulla A, Pepe M, Edgington TS. High level expression of recombinant human tissue factor in Chinese hamster ovary cells as a human thromboplastin. Thromb Haemost 1991; 65: 521-527
• 4 Hawkins P, Tejidor LP, Estevez R, Johnson K, Murza B, Maynard J, Lowrey D, Thom R, Gaur P. Prothrombin time reagents prepared from recombinant human tissue factor produced in E. coli. Thromb Haemost 1991; 65: 1215
• 5 Tripodi A, Arbini A, Chantarangkul V, Mannucci PM. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost 1992; 67: 42-45
• 6 Bader R, Mannucci PM, Tripodi A, Hirsh J, Keller F, Solleder EM, Hawkins P, Peng M, Pelzer H, Teijdor LM, Ramirez IF, Kolde H-J. Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost 1994; 71: 292-299
• 7 Korsan-Bengsten K. Comparison between various methods used to control dicumarol therapy. Acta Med Scand 1970; 188: 327-335
• 8 Poller L, Thomson JM. National survey of value of plasma standards for anticoagulant therapy. Br Med J 1968; 2: 88-90
• 9 Zucker S, Cathey MH, Sox PJ, Hall EC. Standardization of laboratory tests for controlling anticoagulant therapy. Am J Clin Path 1970; 53: 348-354
• 10 British Society for Haematology. Guidelines on oral anticoagulation: second edition. J Clin Path 1990; 43: 177-183
• 11 Poller L. Therapeutic ranges for oral anticoagulation in different thromboembolic disorders. Ann Hematol 1992; 64: 52-59
• 12 Loeliger EA. Therapeutic target values in oral anticoagulation - Justification of Dutch policy and warning against the so-called moderate-intensity regimens. Ann Hematol 1992; 634: 60-65
• 13 Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. PSG Publishing Company; Littleton, USA: 1985
• 14 Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Int Med 1993; 118: 511-520
• 15 Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant therapy. Chest 1992; 102 (Suppl) 352S-363S
• 16 Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-320
• 17 van den Besselaar AMHP. Recommended method for reporting therapeutic control of oral anticoagulant therapy. Thromb Haemost 1990; 63: 316-317
• 18 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875
• 19 Ansell JE. Oral anticoagulant therapy - 50 years later. Arch Intern Med 1993; 153: 586-596
• 20 Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992; 152: 278-282
• 21 Hirsh J. Inadequate monitoring of warfarin disage. Blood 1992; 80: 562-563
• 22 International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 155-156
• 23 Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329: 696-702
• 24 Becker DM, Humphries JE, Walker FB, DeMong LK, Bopp JS, Acker MN. Standardizing the prothrombin time: calibrating coagulation instruments as well as thromboplastins. Arch Pathol Lab Med 1993; 117: 602-605
• 25 Holland LJ, Lawrie AS, Hunt BJ. Evidence of discrepant commercial ISI assignment. Blood Coagul Fibrinolysis 1992; 3: 493-494
• 26 Boekhout-Mussert MJ, van der Kolk-Schap PJ, Hermans J, Loeliger EA. Prospective double-blind clinical trial of bovine, human and rabbit thromboplastins in monitoring long-term oral anticoagulation. Am J Clin Path 1981; 75: 297-303